Get started
CHINA RESOURCES PHARMACEUTICAL GRCHINA RESOURCES PHARMACEUTICAL GRCHINA RESOURCES PHARMACEUTICAL GR

CHINA RESOURCES PHARMACEUTICAL GR

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

3320 chart

Key stats

Market capitalization
‪29.90 B‬HKD
Dividend yield (indicated)
3.57%
Price to earnings Ratio (TTM)
7.64
Basic EPS (TTM)
0.61HKD
Net income
‪3.85 B‬HKD
Revenue
‪244.70 B‬HKD
Shares float
‪1.69 B‬
Beta (1Y)
0.88

About CHINA RESOURCES PHARMACEUTICAL GR

Sector
Health Technology
CEO
Xiao Song Bai
Headquarters
Hong Kong
Website
crpharm.com
Employees (FY)
‪72.99 K‬
Founded
1938
ISIN
HK0000311099
FIGI
BBG00DZWSDQ5
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. It operates through the following segments: Manufacturing, Distribution, Retail, and Others. The Manufacturing segment handles the research and development, manufacture, and sale of pharmaceutical and healthcare products. The Distribution segment focuses on the distribution, warehousing, logistics, and pharmaceutical supply chain solutions and services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. The Retail segment deals with the operation of retailing of pharmacy stores. The Others segment comprises of property holding. The company was founded in 1938 and is headquartered in Hong Kong.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 3320 is 4.78 HKD — it has increased by 1.92% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CHINA RESOURCES PHARMACEUTICAL GR stocks are traded under the ticker 3320.
CHINA RESOURCES PHARMACEUTICAL GR is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
3320 stock is 3.02% volatile and has beta coefficient of 0.88. Check out the list of the most volatile stocks — is CHINA RESOURCES PHARMACEUTICAL GR there?
One year price forecast for CHINA RESOURCES PHARMACEUTICAL GR has a max estimate of 9.30 HKD and a min estimate of 4.90 HKD.
3320 earnings for the last quarter are 0.48 HKD whereas the estimation was 0.23 HKD which accounts for 108.98% surprise. Estimated earnings for the next quarter are 0.20 HKD. See more details about CHINA RESOURCES PHARMACEUTICAL GR earnings.
CHINA RESOURCES PHARMACEUTICAL GR revenue for the last quarter amounts to ‪138.94 B‬ HKD despite the estimated figure of ‪137.92 B‬ HKD. In the next quarter revenue is expected to reach ‪137.27 B‬ HKD.
Yes, you can track CHINA RESOURCES PHARMACEUTICAL GR financials in yearly and quarterly reports right on TradingView.
3320 stock has fallen by 1.85% compared to the previous week, the month change is a 4.97% fall, over the last year CHINA RESOURCES PHARMACEUTICAL GR has showed a 30.52% decrease.
3320 net income for the last quarter is ‪816.19 M‬ HKD, while the quarter before that showed ‪3.04 B‬ HKD of net income which accounts for −73.13% change. Track more CHINA RESOURCES PHARMACEUTICAL GR financial stats to get the full picture.
Today CHINA RESOURCES PHARMACEUTICAL GR has the market capitalization of ‪29.47 B‬, it has decreased by 4.15% over the last week.
Yes, 3320 dividends are paid annually. The last dividend per share was 0.16 HKD. As of today, Dividend Yield (TTM)% is 3.41%. Tracking CHINA RESOURCES PHARMACEUTICAL GR dividends might help you take more informed decisions.
CHINA RESOURCES PHARMACEUTICAL GR dividend yield was 3.31% in 2023, and payout ratio reached 27.66%. The year before the numbers were 2.53% and 24.24% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 3320 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHINA RESOURCES PHARMACEUTICAL GR stock right from TradingView charts — choose your broker and connect to your account.
3320 reached its all-time high on Sep 5, 2018 with the price of 13.16 HKD, and its all-time low was 3.18 HKD and was reached on Dec 20, 2021.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has ‪72.99 K‬ employees. See our rating of the largest employees — is CHINA RESOURCES PHARMACEUTICAL GR on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHINA RESOURCES PHARMACEUTICAL GR technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHINA RESOURCES PHARMACEUTICAL GR stock shows the sell signal. See more of CHINA RESOURCES PHARMACEUTICAL GR technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CHINA RESOURCES PHARMACEUTICAL GR future price: according to them, 3320 price has a max estimate of 9.30 HKD and a min estimate of 4.90 HKD. Read a more detailed CHINA RESOURCES PHARMACEUTICAL GR forecast: see what analysts think of CHINA RESOURCES PHARMACEUTICAL GR and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CHINA RESOURCES PHARMACEUTICAL GR EBITDA is ‪13.70 B‬ HKD, and current EBITDA margin is 5.69%. See more stats in CHINA RESOURCES PHARMACEUTICAL GR financial statements.